Advertisement

Inflammation

pp 1–11 | Cite as

SS31 Ameliorates Sepsis-Induced Heart Injury by Inhibiting Oxidative Stress and Inflammation

  • Yue Liu
  • Wenjian Yang
  • Xiaodong Sun
  • Lixia Xie
  • Yi Yang
  • Ming Sang
  • Rong JiaoEmail author
Original Article

Abstract

Sepsis-induced myocardial dysfunction (SIMD), lack of effective treatment, accounts for high mortality of sepsis. Mitochondrion-targeted antioxidant peptide SS31 has been revealed to be responsible for certain cardiovascular disease by ameliorating oxidative stress injury. But whether it protects a septic heart remains little known. This study sought to prove that SS31 was capable of improving sepsis-induced myocardial dysfunction dramatically. C57BL/6 mice were intraperitoneally administered lipopolysaccharide (LPS), exposed to systemic inflammation. Thirty-five C57BL/6 mice were randomly divided into four groups: sham group, LPS group (5 mg/kg), SS31 group (5 mg/kg), and SS31 + LPS group (treatment group). Heart tissues were harvested for pathological examination at the indicated time points. H9C2 cell were treated with LPS with or without the presence of SS31 (10 μM) at 37 °C to assess the effect on cardiomyocytes at the indicated time points. SS31 restored myocardial morphological damage and suppressed inflammatory response as evidenced by significantly decreasing the mRNA levels of IL-6, IL-1β, and TNF-α in vitro and in vivo. In addition, myocardial energy deficiency secondary to sepsis was remarkedly ameliorated by SS31. Furthermore, we found that SS-31 normalized the activity of malondialdehyde, glutathione peroxidase, and superoxide dismutase in vitro and in vivo, and maintained mitochondrial membrane potential (MMP) as well. And western blot was applied to measure the expressions of p-p38MAPK, p-JNK1/2, p-ERK, p62, and NF-κB p65; the results illuminated that the cardioprotective effect of SS31 was partly linked to NF-κB. In conclusion, SS31 therapy effectively protected the heart against LPS-induced cardiac damage.

KEY WORDS

SS31 SIMD mitochondria inflammation oxidative stress 

Notes

Authors’ Contributions

R.J., M.S., Y.L., and X.D.S. conceived and designed this study. Y.L. carried out experiments. W.J.Y., Y.Y., and L.X.X. collected and analyzed data. W.J.Y. performed statistical analysis. Y.L. and W.J.Y. wrote the manuscript, which was critically reviewed and revised by R.J. and M.S. All authors read and approved the final manuscript.

Funding Information

This investigation was supported by the grants from the Natural Science Foundation of Hubei Province of China (2017CFB674, 2018CFB701), Science and Technology Plan Project of Xiangyang (2014-7-16), the Innovative Team Project (2017-2019) from the Institute of Medicine and Nursing at Hubei University of Medicine, and the Initial Project for Ph.D of Hubei University of Medicine (2015QDJZR03).

Compliance with Ethical Standards

And all the procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication, revised 2011) and were approved by the Ethical Committee for Animal Experimentation of Xiangyang No.1 People’s Hospital.

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

10753_2019_1081_Fig6_ESM.png (36 kb)
Supplementary Fig. 1.

Effects of SS31 on H9C2 cell viability. Cells were treated with different concentrations of SS31 (5, 10, 20, 40, and 80 μM) or LPS (3.125, 6.25, 12.5, 25, 50, 100 and 200 μM) for 12 h. Cell viability was measured and presented as mean ± SEM. H9C2 cells were seeded in 96-well plates, and the result of each concentration was the calculated mean of six wells. (PNG 36 kb)

10753_2019_1081_MOESM1_ESM.tif (82 kb)
High Resolution Image (TIF 82 kb)
10753_2019_1081_Fig7_ESM.png (73 kb)
Supplementary Fig. 2.

SS31 and autophagy. The gene expression of beclin-1, p62, atg3 in heart tissues were estimated by RT-PCR at different time point after LPS or LPS + SS31. The values are expressed as means ± SEM (n = 8 per group). *P < 0.05 vs. control group; #P < 0.05 vs. LPS group. (PNG 72 kb)

10753_2019_1081_MOESM2_ESM.tif (224 kb)
High Resolution Image (TIF 224 kb)

References

  1. 1.
    Kakihana, Y., T. Ito, M. Nakahara, K. Yamaguchi, and T. Yasuda. 2016. Sepsis-induced myocardial dysfunction: pathophysiology and management. Journal of Intensive Care 4: 22.CrossRefGoogle Scholar
  2. 2.
    Tsolaki, V., D. Makris, K. Mantzarlis, and E. Zakynthinos. 2017. Sepsis-induced cardiomyopathy: oxidative implications in the initiation and resolution of the damage. Oxidative Medicine and Cellular Longevity 2017: 7393525.CrossRefGoogle Scholar
  3. 3.
    Drosatos, K., A. Lymperopoulos, P.J. Kennel, N. Pollak, P.C. Schulze, and I.J. Goldberg. 2015. Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both? Current Heart Failure Reports 12 (2): 130–140.CrossRefGoogle Scholar
  4. 4.
    Liu, Y.C., M.M. Yu, S.T. Shou, and Y.F. Chai. 2017. Sepsis-induced cardiomyopathy: mechanisms and treatments. Frontiers in Immunology 8 (1): 1021.CrossRefGoogle Scholar
  5. 5.
    Okuhara, Y., S. Yokoe, T. Iwasaku, A. Eguchi, K. Nishimura, W. Li, M. Oboshi, Y. Naito, T. Mano, M. Asahi, H. Okamura, T. Masuyama, and S. Hirotani. 2017. Interleukin-18 gene deletion protects against sepsis-induced cardiac dysfunction by inhibiting PP2A activity. International Journal of Cardiology 243: 396–403.CrossRefGoogle Scholar
  6. 6.
    Stanzani, G., M.R. Duchen, and M. Singer. 2018. The role of mitochondria in sepsis-induced cardiomyopathy. Biochimica et Biophysica Acta - Molecular Basis of Disease 1865 (4): 759–773.Google Scholar
  7. 7.
    Joseph, L.C., D. Kokkinaki, M.C. Valenti, G.J. Kim, E. Barca, D. Tomar, N.E. Hoffman, P. Subramanyam, H.M. Colecraft, M. Hirano, A.J. Ratner, M. Madesh, K. Drosatos, and J.P. Morrow. 2017. Inhibition of NADPH oxidase 2 (NOX2) prevents sepsis-induced cardiomyopathy by improving calcium handling and mitochondrial function. JCI Insight 2 (17).Google Scholar
  8. 8.
    Cohen, J., S. Opal, and T. Calandra. 2012. Sepsis studies need new direction. The Lancet Infectious Diseases 12 (7): 503–505.CrossRefGoogle Scholar
  9. 9.
    Tang, G., H. Yang, J. Chen, M. Shi, L. Ge, X. Ge, and G. Zhu. 2017. Metformin ameliorates sepsis-induced brain injury by inhibiting apoptosis, oxidative stress and neuroinflammation via the PI3K/Akt signaling pathway. Oncotarget 8 (58): 97977–97989.Google Scholar
  10. 10.
    Hu, D., X. Yang, Y. Xiang, H. Li, H. Yan, J. Zhou, Y. Caudle, X. Zhang, and D. Yin. 2015. Inhibition of Toll-like receptor 9 attenuates sepsis-induced mortality through suppressing excessive inflammatory response. Cellular Immunology 295 (2): 92–98.CrossRefGoogle Scholar
  11. 11.
    Durand, A., T. Duburcq, T. Dekeyser, R. Neviere, M. Howsam, R. Favory, and S. Preau. 2017. Involvement of mitochondrial disorders in septic cardiomyopathy. Oxidative Medicine and Cellular Longevity 2017: 4076348.CrossRefGoogle Scholar
  12. 12.
    Luiking, Y.C., M. Poeze, and N.E. Deutz. 2015. Arginine infusion in patients with septic shock increases nitric oxide production without haemodynamic instability. Clinical Science (London, England : 1979) 128 (1): 57–67.CrossRefGoogle Scholar
  13. 13.
    Zhang, Y., X. Xu, A.F. Ceylan-Isik, M. Dong, Z. Pei, Y. Li, and J. Ren. 2014. Ablation of Akt2 protects against lipopolysaccharide-induced cardiac dysfunction: role of Akt ubiquitination E3 ligase TRAF6. Journal of Molecular and Cellular Cardiology 74 (undefined): 76–87.CrossRefGoogle Scholar
  14. 14.
    Szekely, Y., and Y. Arbel. 2018. A review of interleukin-1 in heart disease: where do we stand today? Cardiology and Therapy 7 (1): 25–44.CrossRefGoogle Scholar
  15. 15.
    Alvarez, S., T. Vico, and V. Vanasco. 2016. Cardiac dysfunction, mitochondrial architecture, energy production, and inflammatory pathways: interrelated aspects in endotoxemia and sepsis. The International Journal of Biochemistry & Cell Biology 81 (null): 307–314.CrossRefGoogle Scholar
  16. 16.
    Siasos, G., V. Tsigkou, M. Kosmopoulos, D. Theodosiadis, S. Simantiris, N.M. Tagkou, A. Tsimpiktsioglou, P.K. Stampouloglou, E. Oikonomou, K. Mourouzis, A. Philippou, M. Vavuranakis, C. Stefanadis, D. Tousoulis, and A.G. Papavassiliou. 2018. Mitochondria and cardiovascular diseases-from pathophysiology to treatment. Annals Translational Medicine 6 (12): 256.CrossRefGoogle Scholar
  17. 17.
    Cho, S., H.H. Szeto, E. Kim, H. Kim, A.T. Tolhurst, and J.T. Pinto. 2007. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. The Journal of Biological Chemistry 282 (7): 4634–4642.CrossRefGoogle Scholar
  18. 18.
    Zhang, M., H. Zhao, J. Cai, H. Li, Q. Wu, T. Qiao, and K. Li. 2017. Chronic administration of mitochondrion-targeted peptide SS-31 prevents atherosclerotic development in ApoE knockout mice fed Western diet. PLoS One 12 (9): e0185688.CrossRefGoogle Scholar
  19. 19.
    Lu, H.I., F.Y. Lee, C.G. Wallace, P.H. Sung, K.H. Chen, J.J. Sheu, S. Chua, M.S. Tong, T.H. Huang, Y.L. Chen, P.L. Shao, and H.K. Yip. 2017. SS31 therapy effectively protects the heart against transverse aortic constriction-induced hypertrophic cardiomyopathy damage. American Journal of Translational Research 9 (12): 5220–5237.Google Scholar
  20. 20.
    Ma, W., X. Zhu, X. Ding, T. Li, Y. Hu, X. Hu, L. Yuan, L. Lei, A. Hu, Y. Luo, and S. Tang. 2015. Protective effects of SS31 on tBHP induced oxidative damage in 661W cells. Molecular Medicine Reports 12 (4): 5026–5034.CrossRefGoogle Scholar
  21. 21.
    Zhang, Chang-xiong, Ying Cheng, Dao-zhou Liu, Miao Liu, Han Cui, Bang-le Zhang, Qi-bing Mei, and Si-yuan Zhou. 2019. Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats. Journal of Nanobiotechnology 17 (1): 18.CrossRefGoogle Scholar
  22. 22.
    Li, G., J. Wu, R. Li, D. Yuan, Y. Fan, J. Yang, M. Ji, and S. Zhu. 2016. Protective effects of antioxidant peptide SS-31 against multiple organ dysfunctions during endotoxemia. Inflammation 39 (1): 54–64.CrossRefGoogle Scholar
  23. 23.
    Brown, M.A., and W.K. Jones. 2004. NF-kappaB action in sepsis: the innate immune system and the heart. Frontiers in Bioscience 9: 1201–1217.Google Scholar
  24. 24.
    Zhang, E., X. Zhao, L. Zhang, N. Li, J. Yan, K. Tu, R. Yan, J. Hu, M. Zhang, D. Sun, and L. Hou. 2019. Minocycline promotes cardiomyocyte mitochondrial autophagy and cardiomyocyte autophagy to prevent sepsis-induced cardiac dysfunction by Akt/mTOR signaling. Apoptosis 24 (3-4): 369–381.CrossRefGoogle Scholar
  25. 25.
    Doerrier, C., J.A. García, H. Volt, M.E. Díaz-Casado, M. Luna-Sánchez, B. Fernández-Gil, G. Escames, L.C. López, and D. Acuña-Castroviejo. 2016. Permeabilized myocardial fibers as model to detect mitochondrial dysfunction during sepsis and melatonin effects without disruption of mitochondrial network. Mitochondrion 27 (undefined): 56–63.CrossRefGoogle Scholar
  26. 26.
    Zang, Q., D.L. Maass, S.J. Tsai, and J.W. Horton. 2007. Cardiac mitochondrial damage and inflammation responses in sepsis. Surgical Infections 8 (1): 41–54.Google Scholar
  27. 27.
    Niu, J., K. Wang, S. Graham, A. Azfer, and P.E. Kolattukudy. 2011. MCP-1-induced protein attenuates endotoxin-induced myocardial dysfunction by suppressing cardiac NF-κB activation via inhibition of IκB kinase activation. Journal of Molecular and Cellular Cardiology 51 (2): 177–186.Google Scholar
  28. 28.
    Siegel, M.P., S.E. Kruse, J.M. Percival, J. Goh, C.C. White, H.C. Hopkins, T.J. Kavanagh, H.H. Szeto, P.S. Rabinovitch, and D.J. Marcinek. 2013. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell 12 (5): 763–771.CrossRefGoogle Scholar
  29. 29.
    S. HH. 2014. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology 171 (8): 2029–2050.CrossRefGoogle Scholar
  30. 30.
    Wang, Li, Yang Li, Na Ning, Jin Wang, Zi Yan, Suli Zhang, Xiangying Jiao, Xiaohui Wang, and Huirong Liu. 2018. Decreased autophagy induced by β-adrenoceptor autoantibodies contributes to cardiomyocyte apoptosis. Cell Death & Disease 9 (3): 406.CrossRefGoogle Scholar
  31. 31.
    Barile, L., V. Lionetti, E. Cervio, M. Matteucci, M. Gherghiceanu, L.M. Popescu, T. Torre, F. Siclari, T. Moccetti, and G. Vassalli. 2014. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovascular Research 103 (4): 530–541.CrossRefGoogle Scholar
  32. 32.
    Li, J., D. Zhang, M. Wiersma, and B. Brundel. 2018. Role of autophagy in proteostasis: friend and foe in cardiac diseases. Cells 7 (12).Google Scholar
  33. 33.
    Sun, Y., X. Yao, Q.J. Zhang, M. Zhu, Z.P. Liu, B. Ci, Y. Xie, D. Carlson, B.A. Rothermel, Y. Sun, B. Levine, J.A. Hill, S.E. Wolf, J.P. Minei, and Q.S. Zang. 2018. Beclin-1-dependent autophagy protects the heart during sepsis. Circulation 138 (20): 2247–2262.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pediatrics, Xiangyang No.1 People’s HospitalHubei University of MedicineXiangyangPeople’s Republic of China

Personalised recommendations